Junshi biology: Aurora A inhibitor js112 clinical trial application accepted
Financial Associated Press, November 29 - Junshi biology announced that Aurora A inhibitor js112 obtained the notice of acceptance of drug clinical trial application; A new indication of treprizumab combined with cisplatin and gemcitabine for first-line treatment of patients with locally recurrent or metastatic nasopharyngeal carcinoma was approved.
This text is a result of machine translation.
Related companies：
Briefing Jun 28, 2022 11:10 AM
· Automotive
GAC group released a new generation of microcrystalline technology, and the volume energy density of super energy iron lithium battery increased by 20%
In-depth
Healthcare
China's First Oral COVID-19 Antiviral Medicine in Dispute
An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.
Aug 08, 2022 09:00 AM
Briefing May 24, 2022 02:24 PM
· Healthcare
Zelensky called on the international community to provide funds for Ukraine's reconstruction, which is expected to cost $500 billion
Jan 06, 2023 08:30 AM
Nov 16, 2022 05:19 PM
Nov 08, 2022 08:32 AM
Nov 07, 2022 04:27 PM
Briefing May 21, 2022 06:44 AM
· Financials
913 companies have been investigated by public funds since the second quarter, and the six top flow fund managers focus on the leaders of subdivided industries
Healthcare
Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab
The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.
Sep 20, 2022 03:35 PM
In-depth
See more
Read next
Insight
In-depth
Insight
In-depth